SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009, in Orlando, Florida. Chidamide/HBI-8000 is a novel benzamide class histone deacetylase (HDAC) inhibitor in development by Chipscreen and HUYA for oncology indications. The data to be presented will include safety, pharmacokinetics, and biomarker and anti-tumor activity (abstract #3529).
Title: "Phase 1 study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas" Poster Presentation: Friday, May 29, 2 pm - 6 pm EDT, Level 3, W315A, Board 13 Poster Discussion: Friday, May 29, 5 pm - 6 pm EDT, Level 4, Valencia Room, W415D
Shenzhen Chipscreen Biosciences is a leading China-based biotechnology company that specializes in discovering and developing proprietary small molecule therapeutics for unmet medical needs. The company is utilizing its proprietary chemical genomics-based discovery platform to develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. The core competence of the company is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise. Additional information about the company is available at www.chipscreen.com.
HUYA Bioscience International is a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to enhance development efficiency and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the worldwide value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at www.huyabio.com.
Contact: For Chipscreen: For HUYA: Sophie Cao, M.D. Michael Newman, Ph.D. Head of Medical Affairs Executive Vice President, Oncology +86 755 26719670 +1 858 798-8800 +86 138 23171987 mobile +1 858 922-9015 mobile Zhi-Qiang Ning, M.D., Ph.D. Juliet Travis (media contact) Vice President, R&D +1 510 452-3771 +86 755 26957727 +86 139 24590432 mobile
|SOURCE HUYA Bioscience International, LLC|
Copyright©2009 PR Newswire.
All rights reserved